Trading Halt Active
This ticker is currently halted. Check the Halts tab for details.
Volatility Alert
This ticker is experiencing unusual price movement.
Key Stats
Day Range
$1.99
$2.13
52-Week Range
$1.99
$6.44
14-Day RSI
-
Upcoming Earnings
---
---
Volume
-
Analyst Rating
-
-
-
-
Price Target
-
-
Last Earnings
-
-
About
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Valuation
396.82M
Market Cap
-
Forward P/E
-
Trailing P/E
-
Price/Book
-
EPS (TTM)
Financial Snapshot
-
Revenue (TTM)
-
EBITDA
-
Free CF
-
Total Debt
-
Beta
Margins & Dividends
-
Gross Margin
-
Op. Margin
-
Div Rate
-
Div Yield
-
Ex-Div Date
Profile
-
Sector
-
Industry
-
Short % Float
Nearest Expiry:
Loading...
Max Pain:
$0.00
Support (Put Wall)
$0.00
OI: 0
Current Price
$0.00
Resistance (Call Wall)
$0.00
OI: 0
Calls
Loading...
Puts
Loading...
Unusual Whale Flow
Loading anomaly scanner...
Experimental. Executive-branch trades are sourced from a third-party aggregator (open-cabinet.org) that parses OGE filings — not yet independently verified. Most executive-branch filings are bonds; only trades resolved to an equity ticker appear here.